Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?
Preprint
- 28 June 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Objectives: Aromatase inhibitor induced bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. We aimed to determine the real-world impact of the 2017 consensus guidelines on AIBL and it is effective in fracture prevention. Methods: Over a 7-year study period, 1001 women prescribed AI were split in two groups. First group were offered bone active treatment based on NOS 2009 guidelines whereas the second group followed the 2017 consensus guidelines. Results: 1001 women were included. First group: 361 women had a baseline DEXA with 143 (40%) women had a normal DEXA, 174 (48%) had osteopenia and 44 (12%) had osteoporosis. Of the women with osteopenia, 44 (25%) women were offered treatment and 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with 216 (33%) women were normal, 322(50%) had osteopenia and 107 (17%) had osteoporosis. Of the women with osteopenia, 127 (39%) women were offered treatment and 8 (2.5%) women had a fracture. Conclusions: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity.Keywords
All Related Versions
- Version 1, 2023-06-28, Research Square
- Published version: BJC Reports, 2 (1), 1.
This publication has 15 references indexed in Scilit:
- Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort StudyJournal of Bone and Mineral Research, 2019
- Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal womenCalcified Tissue International, 2019
- Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysisTherapeutic Advances in Musculoskeletal Disease, 2018
- Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOGJournal of Bone Oncology, 2017
- Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional studyBone, 2017
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialThe Lancet Oncology, 2010
- Changes in Bone Mineral Density After Adjuvant Aromatase Inhibitors and Fracture Risk in Breast Cancer PatientsJournal of Clinical Oncology, 2007
- Aromatase Inhibitors and Bone Health in Women With Breast CancerJournal of Clinical Oncology, 2006
- Bone Loss and Fracture Risk Associated with Cancer TherapyThe Oncologist, 2006